Volume 2, # 1 - May, 1996
Table of Contents
|
| STATE-OF-THE-ART MANAGEMENT OF CANCER |
| PROSTATE CANCER - PART I |
| Epidemiology |
282 |
| Prostate Anatomy, Histology and Cancer Pathology |
284 |
| Etiology and Pathogenesis |
284 |
| Genetic Factors |
284 |
| Growth Factors |
286 |
| Screening and Chemoprevention |
287 |
| Screening Using PSA |
287 |
| Chemoprevention |
288 |
| Diagnosis |
288 |
| Prostate Specific Antigen (PSA) |
288 |
| Other Biomarkers |
289 |
| AntiCancer |
289 |
| Cytogen |
289 |
| DIANON Systems |
289 |
| Horus Therapeutics |
290 |
| Matritech |
290 |
| Oncor |
290 |
| Biopsy |
290 |
| Radionuclide Bone Scans |
291 |
| Radioimmunoscintigraphy |
291 |
| Other Diagnostic Tests |
291 |
| Optical Imaging |
291 |
| Staging |
291 |
| Prognosis |
291 |
| Treatment of Prostate Cancer |
292 |
| Treatment of Localized Prostate Cancer |
292 |
| Radical prostatectomy |
293 |
| Neoadjuvant hormonal ablation therapy |
293 |
| External beam radiation therapy |
295 |
| Brachytherapy |
295 |
| Cryotherapy |
295 |
| Hyperthermia |
296 |
| Photodynamic therapy |
296 |
| Fast neutron therapy |
297 |
| Boron neutron capture therapy |
297 |
| MEETING COVERAGE |
|
ADVANCES IN THE TREATMENT OF PROSTATE CANCER
From the 32nd Annual Meeting of the American Society of Clinical Oncology
Philadelphia, PA - May 18-21, 1996 |
|
| PSA Level as Predictor of Survival Following Prostate Cancer Radiation Therapy |
298 |
| Combined Modality Therapy In Locally-Advanced Disease |
298 |
| Anti-androgens in Previously Untreated Metastatic Prostate Cancer |
298 |
| Potency Sparing Therapy for Advanced Disease |
299 |
| Treatment of Hormone Refractory Prostate Cancer |
299 |
